Power wheelchair — group 2 denied as not FDA-approved for this use by UnitedHealthcare?

Under UnitedHealthcare's Commercial medical policy, mobility devices including manual wheelchairs, electric wheelchairs, transfer chairs, scooters/power-operated vehicles (POV), canes, and walkers are a covered health care service when medically necessary. The policy aligns with CMS LCD L33789, which establishes that the beneficiary must have a mobility limitation that significantly impairs his/her ability to participate in one or more mobility-related activities of daily living (MRADLs) such as toileting, feeding, dressing, grooming, and bathing in customary locations in the home — a limitation that prevents the beneficiary from accomplishing an MRADL entirely, places the beneficiary at heightened risk of morbidity or mortality, or prevents completing an MRADL within a reasonable time frame ; additionally, the mobility limitation cannot be sufficiently and safely resolved by an appropriately fitted cane or walker, and the beneficiary does not have sufficient upper extremity function to self-propel an optimally-configured manual wheelchair in the home to perform MRADLs during a typical day. Use of a power wheelchair must significantly improve the beneficiary's ability to participate in MRADLs and the beneficiary will use it in the home (for severe cognitive/physical impairments, participation in MRADLs may require caregiver assistance), and the beneficiary has not expressed an unwillingness to use a power wheelchair in the home. For a Group 2 standard PWC, a Group 2 PWC (K0820, K0821, K0822, K0823, K0824, K0825, K0826, K0827, K0828, K0829) is covered if all of the coverage criteria (a)-(e) for a PWC are met and the wheelchair is appropriate for the beneficiary's weight. For a Group 2 Single Power Option PWC, all coverage criteria (a)-(e) must be met, plus the beneficiary meets coverage criteria for a power tilt or recline seating system OR requires a drive control interface other than a hand or chin-operated standard proportional joystick (examples include head control, sip and puff, switch control) , and a specialty evaluation must be performed by a licensed/certified medical professional (PT, OT, or practitioner with rehab wheelchair training) with no financial relationship with the supplier, and the wheelchair must be provided by a supplier that employs a RESNA-certified Assistive Technology Professional (ATP) with direct, in-person involvement in the wheelchair selection. DME has a reasonable useful lifetime (RUL) of 5 years , and payment is made for only one wheelchair at a time; backup chairs are denied as not reasonable and necessary.

- **Document MRADL impact in detail**: Provide a clinician note specifying which MRADLs (toileting, feeding, dressing, grooming, bathing) the patient cannot complete or completes only with heightened morbidity/mortality risk, directly mapping to the LCD L33789 definition of a qualifying mobility limitation . - **Stepwise rule-out of lesser devices**: Submit PT/OT documentation explaining why a cane, walker, and optimally-configured manual wheelchair each fail — addressing strength, endurance, ROM, coordination, pain, or upper-extremity deformity per the LCD's enumerated upper-extremity assessment factors (strength, endurance, range of motion, coordination, pain, deformity or absence of one or both upper extremities) . - **Provide compliant face-to-face and WOPD**: Attach the dated face-to-face mobility examination note and the signed Standard Written Order before delivery; cite Final Rule 1713's requirement of a face-to-face encounter and Written Order Prior to Delivery as satisfied. - **Include RESNA ATP and independent specialty evaluation**: For Group 2 Single Power Option chairs, include both the ATP credential attestation and the independent PT/OT specialty evaluation, satisfying the requirement that a licensed PT/OT with no financial relationship to the supplier perform the specialty evaluation and that a RESNA-certified ATP have direct involvement in wheelchair selection . - **Demonstrate in-home use**: Document home assessment showing adequate access between rooms and maneuvering space, and explicitly state the device will be used in the home to meet the requirement that the beneficiary's home provides adequate access and that the power wheelchair will significantly improve the beneficiary's ability to participate in MRADLs in the home . - **Justify Group 2 over Group 1**: If denied as needing only a Group 1, document the patient's weight against capacity limits or, for Single Power Option, the medical necessity of power tilt/recline (e.g., pressure ulcer risk, inability to perform a functional weight shift) or alternative drive control interface per LCD L33789 Group 2 Single Power Option criteria including need for non-standard drive control such as head control, sip and puff, or switch control . - **Replacement vs. repair**: For replacement requests, document the 5-year RUL and that the existing chair cannot be repaired or no longer meets the patient's needs, citing the 5-year reasonable useful lifetime standard and UHC's allowance for upgrades when the member's condition changes (e.g., impaired function necessitates an upgrade to a power wheelchair from a manual one) .

## Why UnitedHealthcare Denied Your Group 2 Power Wheelchair as "Not FDA-Approved"

Power wheelchairs are durable medical equipment (DME), not drugs, so FDA "approval" in the traditional sense does not apply. However, insurers including UnitedHealthcare require that DME meet applicable federal regulatory standards and that the specific device model appear on an approved supplier or product list. A denial coded as "not FDA-approved" for a power wheelchair typically means UHC's system flagged the device code, the product registration status, or a billing code mismatch — not that the chair is inherently unsafe or ineligible.

## Why This Denial Is Appealable

Group 2 power wheelchairs are a recognized, standard category of DME under Medicare-aligned coverage guidelines that most commercial insurers, including UHC, incorporate by reference. If the device your prescriber ordered meets the product-registration and billing-code requirements, the denial label is factually incorrect and should be reversed on appeal.

## Federal Appeal Framework

• Internal appeal: You have the right to a full internal appeal under ERISA §503 (employer plans) or applicable state law (fully insured plans). Submit within the deadline stated on your Explanation of Benefits (EOB), typically 180 days.
• External review: After exhausting internal appeals — or if UHC fails to decide within the required timeframe — you may request independent external review under ACA §2719. The external reviewer is not employed by UHC and must issue a binding decision.
• Expedited option: If waiting the standard timeline would seriously jeopardize your health or mobility, request an expedited (urgent) appeal. Decisions are typically required within 72 hours internally and 72 hours at the external-review stage.
• Window: External review must generally be requested within four months of a final internal denial.

## Concrete Appeal Steps

1. Request the full denial letter and your plan's Summary Plan Description (SPD) or Coverage Determination Guidelines for DME. 2. Obtain the exact product registration information, HCPCS billing code, and manufacturer documentation for the chair. 3. Have your prescribing physician or physiatrist write a letter confirming the device meets applicable federal and UHC DME requirements. 4. Submit a written internal appeal with all documentation attached. 5. If denied again, file for external review immediately.

## Documentation to Gather

• Diagnosis records confirming the underlying mobility-limiting condition
• Functional assessment by a physician or licensed therapist documenting inability to use a manual or lower-level power wheelchair
• Manufacturer product documentation and FDA 510(k) or equivalent registration record
• HCPCS code confirmation from the DME supplier
• Prescriber letter of medical necessity

## Criteria-Mapping Structure

Pull UHC's published DME coverage policy for Group 2 power wheelchairs. For each requirement listed, document the exact chart fact that satisfies it. Common requirements include mobility limitation diagnosis, functional assessment findings, and device classification — answer each point-by-point with dated clinical records.